GLP1R and type 2 diabetes mellitus: The determinants of compensatory increase in cardiac GLP-1R expression are incompletely understood24 and thus, the possible effects of type 2 diabetes, anti-inflammatory therapy, or therapies activating GLP-1R signaling on cardiac GLP-1R expression and 68Ga-NODAGA-exendin-4 uptake should be studied.